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ABSTRACT
EBV has two lytic origins (oriLyt) of DNA replication
lying at divergent sites on the viral genome within
a duplicated sequence (DS). The latter contains
potential hairpin loops, ‘hinge’ elements and the
promoters for transcripts from viral genes BHLF1
and LF3. These genes themselves consist largely of
125 and 102bp repetitive sequences, respectively,
and encode basic proteins. We have examined
these genomic regions in detail in attempts to
understand why lytic replication—necessary for
virus survival—is so inefficient, and to identify
controlling elements. Our studies uncovered a
diverse family of promoters (P) for BHLF1 and LF3,
only one pair of which (P1) proved sensitive to
chemical inducing agents. The others (P2–P3/4),
abutting the replication ‘core’ origin elements in DS
and extending into 50-unique sequences, may play
roles in the maintenance of viral latency. We further
identified a family of overlapping small complemen-
tary-strand RNAs that transverse the replication
‘core’ origin elements in a manner suggesting a role
for them as ‘antisense’ species and/or DNA replica-
tion primers. Our data are discussed in terms of
alternative lytic replication models. We suggest
our findings might prove useful in seeking better
control over viral lytic replication and devising
strategies for therapy.
INTRODUCTION
Epstein–Barr virus (EBV), a DNA virus and member
of the herpesvirus family, has infected most humans
(490%) by the time they reach adulthood, infection
having occurred orally at an early age in crowded
populations, but often much later in less-populous
communities. EBV is best known in Western societies
for its association with the time-limited disease, infectious
mononucleosis (IM) and more recently with a B-cell post-
transplant lymphoproliferative disease (PTLD) that can
occur in EBV-positive individuals following immunosup-
pressive therapy. The virus is also associated with a
variety of solid tumours whose types and frequencies
diﬀer in their geographical locations (1). In sub-Saharan
Africa, EBV infection contributes to the development of
the B-cell malignancy, Burkitt’s lymphoma (BL), the most
prevalent cancer among children there (1–3). In Asia,
particularly southern China, EBV is associated with an
epithelial cell malignancy of adults, (undiﬀerentiated)
nasopharyngeal carcinoma (NPC) (1,2). At lesser fre-
quencies, the virus appears as a component of a variety of
other malignancies worldwide (1). Both geography and
viral load may play roles in the development of speciﬁc
tumours (1,4). The complete sequence of the EBV
genome, a tour de force in its time (5), has stimulated
work on the 100 or so viral genes associated with
malignancy and/or the viral life cycle, as reviewed (6).
In virions, EBV DNA exists as a double-stranded linear
molecule with repetitive sequences at each terminus (TR)
and unique sequences separated at roughly equal
intervals by internal repeats (IR1-IR4)—mimicking as
such the chromosomal organization of its human host.
Recombination events at the TRs lead to generation of
a circular, supercoiled plasmid species, the prevalent form
of EBV found in infected cells. Repeat copy numbers
dictate the genome size (from 170 to4200kb) in diﬀerent
strains of the virus (7).
Lytic replication, essential for virus spread, appears
to occur predominantly in epithelial cells within the
oropharynx (6). For a number of oncogenic DNA viruses,
notably papilloma or hepatitis B, no in vitro replication
system has been found for producing progeny virus.
For EBV, some viral strains undergo limited spontaneous
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to replicate (8,9), and a third category shows no response
to external reagents. No fully competent in vitro lytic
system has, however, ever been identiﬁed. Of its three viral
origins of replication, one (oriP) serves for EBV plasmid
(supercoiled circular) replication whilst the other two
(oriLyt L and R) act as sites for linear lytic replication.
EBV remains mainly in its plasmid form in most infected
human cells, replicating once per cell cycle (10). Its oriP—
which structurally resembles replication origins of a
number of other DNA viruses—has been studied in
considerable detail, as have the so-called ‘latent’ viral
and host genes associated with replication from this
site (as reviewed 11). As yet less well-deﬁned is the
lytic mode of viral replication, although early work by
Hammerschmidt and Sugden (8) suggested a complexity
greater than that seen with the small DNA tumour viruses,
Chavallier-Greco et al. (13) identiﬁed two EBV-encoded
genes (designated EB1 and EB2) with the capacity to
disrupt latency in infected cells, and Anisimova et al. (14)
showed n-butyrate and the phorbol ester, TPA, to
facilitate this process. Current data, including those in
this manuscript, appear to support a remarkably high level
of complexity, which, when understood, should increase
our capacity to control this human oncogenic virus.
The two distinct genomic regions (DS) directly asso-
ciated with viral lytic replication are located within
duplicated sequences DL and DR (where L¼left and
R¼right on the conventional EBV physical map;
see Figure 1) adjacent to open reading frames BHLF1
(in the case of oriLytL) and LF3 (for oriLytR), whose
transcripts specify proteins containing tandem repeat
sequences, IR2 and IR4, respectively. BHLF1 and LF3
notably are the most abundant polyA
þ viral transcripts
expressed, particularly in chemically induced cells (15).
Whereas some EBV genomes lack one or other of the
oriLyt regions, no genome—even in strains that cannot
be induced to express virus—has ever been identiﬁed
which lacks both. Structural elements in the genome,
within the duplicated sequence (DS) regions, appear to be
essential for lytic replication. One structure involves
‘palindromic’ sequences that permit hairpin loop forma-
tions—as seen with origins of replication in other DNA
viruses—and another allows for the potential existence of
a ‘hinge’ (H) structure, with single- and triple-stranded
elements (16). Expression of several viral transactivator
functions that induce transcriptional expression of EBV
lytic cycle-related early genes (17–19), the transcripts
themselves (8) or a gene product that exports mRNA from
the nucleus (19), also appear to be essential. The need for
two lytic origins of replication has not been deﬁned but,
notably, another human herpesvirus, Kaposi sarcoma
herpesvirus (KSH or HHV-8) also possesses two func-
tional lytic origins of DNA replication (20). The topic of
EBV lytic replication has been recently reviewed (12,21).
Our initial interest in the regions encoding BHLF1
and LF3, immediately adjacent to the viral oriLyts, was
stimulated by the fact that they may represent potentially
important therapeutic targets in EBV-associated tumours.
Their expression can be identiﬁed in subpopulations of
cells in many such tumours (22,23), in a manner partly
dependent upon the nature of the host cell. The basic
(arginine/histidine-rich) protein product of BHLF1 has
been shown to bind, preferentially, single-stranded DNA,
and a structurally similar protein within LF3 postulated
to behave in the same manner (24,25). Studies aimed at
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Figure 1. EBV genome features associated with DNA lytic replication. Features shown are: (A) Truncated linear representation of the viral genome
with map units relating to nucleotide sequence numbers (accession number AJ507799). BamHI DNA restriction fragments are conventionally
designated alphabetically, according to size and site on the genome; locations of gene deletions (solid lines) in some viral isolates, as noted, are
shown. In Daudi cells, a deletion removes the EBV BHLF1 gene and its promoter elements, as indicated; a smaller deletion in P3HR-1 (not shown)
removes the gene but not its promoter sequences (31). In B95-8 cells, a deletion removes EBV LF3 coding and promoter elements. (B) A simpliﬁed
version of the genome, indicating locations of tandem repetitive sequences IR1 (in BamHI W), IR2 (in BamHI H), IR4 (in BamHI Ia), as well as
the terminal repeats (TR), the plasmid (oriP) and two lytic (oriLyts) origins of replication—the latter two within duplicated regions, DL and DR.
(C) Expanded genomic regions indicating compositions and polarity of the viral genes, BHLF1 and LF3 that contain repeats which can be cleaved
with NotI and PstI restriction enzymes, respectively, also the two oriLyt ‘core’ regions (boxes; see ref. 8). 30-50 polarities are used here since both
BHLF1 and LF3 are expressed in a leftward orientation on the conventional EBV physical map, as given in (A).
3392 Nucleic Acids Research, 2007, Vol. 35, No. 10localizing ‘core replication’ elements identify a number
of viral genes that are functionally relevant to lytic
replication (26,27). Unlike the situation with the small
DNA viruses, however, here no dedicated origin-binding
protein was identiﬁed. More recently the work of
Baumann et al. (28) has implicated cellular transcription
factors that act as ‘bridging’ proteins for replication
complexes and play essential roles in viral lytic replication.
Earlier, Metzenberg (29), carrying out ‘run on’ transcrip-
tion experiments on isolated infected cell nuclei, noted
that in some instances as much as 50% of the transcrip-
tional expression of BHLF1 appeared to come from 50
regions ‘upstream’ of an identiﬁed promoter. Interestingly,
this topic was not apparently further pursued.
Early studies using M-ABA cells (15) focused on
expression of BHLF1 and LF3 controlled from a pair
(P1) of promoter-related sites located in DS, in regions
contiguous to the genes. Most studies relating to their
transcriptional expression, in that they use cell lines
(B95-8, Daudi, P3HR-1) carrying deletions of one or
other of the genes (e.g. refs. 16, 29-31), do not allow for
comparative expression studies of the two sites to be
made. The tacit assumption appears to be that their genes
and expressions are interchangeable. However, control
sequences for BHLF1 and LF3 lie within diﬀerent genetic
environments (Figure 1) and our earlier studies identiﬁed
host-cell diﬀerences in expression in virus-associated
tumours, indicative of non-identity (22,23). Moreover,
the genes themselves express non-identical basic proteins.
Because of their presumed relevance to the viral life cycle,
and their potential for exploitation, we have here
examined expression control for BHLF1 and LF3 in
parallel, both in cell lines and fresh EBV-positive tumours
of B- or epithelial-cell origins, most of which retain the
genetic information for both genes. Our data reveal for
them—in addition to the P1 pair of promoter-related
sequences (15)—a pattern of multiple promoters that can
only in part be superimposed. These promoters, unlike P1,
are not susceptible to chemical induction, yet appear to be
functionally active and specify transcripts relating to
BHLF1 and LF3. In addition, in the present study, we
present data showing the complementary strand also to be
transcriptionally active and to encode a family of small
(antisense) RNA transcripts initiating in DS regions,
associated with the oriLyts. We have conﬁrmed host-cell
expression diﬀerences between the two genes and ‘revisit’
the topic of lytic EBV replication with the aim of using the
new data for obtaining better control over it.
MATERIALS AND METHODS
Tumour biopsies, cell lines and propagation
Primary NPC biopsies were obtained from Prof. M.H. Ng
(Department of Microbiology) and Dr J. Nichols
(Department of Pathology), Queen Mary Hospital,
Hong Kong University, and NPC xenografts (C15, C17
and C18) from Dr P. Busson, Villejuif, France. The latter
were propagated in athymic (nude) mice as described (32).
Induction of EBV in the C15 xenograft has been described
elsewhere (22). Surgically removed lymphoma biopsies,
provided by Prof. E. Borgstein, the Medical College,
Blantyre, Malawi, were identiﬁed as Burkitt’s (non-
Hodgkin’s) lymphoma (BLs) by histopathology. CC is
an EBV negative African lymphoma, from the same
source. All tumours were suspended in maintenance media
(foetal calf serum/DMSO) and stored in liquid nitrogen
prior to use. BL-derived EBV-positive cell lines studied for
expression of lytic-related genes, as described (23), were of
marmoset (B95-8, M-ABA—generated with human EBV)
or human (Raji, Daudi, P3HR-1, BL74—tumour-derived)
origins; Ramos is an EBV-negative B-cell line. Cells were
grown in suspension culture under standard conditions,
with or without chemical induction, as described (22).
Isolationof RNA, cDNA synthesis and RT-PCR
amplification
Total RNAs from fresh biopsies, xenografts or cell
lines were isolated by the guanidinium–caesium
chloride method, and polyadenylated (polyAþ) RNAs
selected on oligo(dT) mRNA puriﬁcation columns
(Pharmacia), as described (22). RNAs were quantiﬁed by
uv-spectrophotometry (1.0 uv-absorbance reading for
RNA at 260nm corresponding to 40mg/ml for single-
stranded RNA). To remove any residual DNA, total
(5mg) or (polyAþ)( 1 mg) RNAs were treated with 10 U
DNaseI (Boehringer) in 10mM Tris–HCl (pH 7.5), 10mM
MgCl2, 50mM NaCl, 1mM dithiothreitol, brieﬂy mixed,
incubated at 378C (30min) and the solution extracted (2 )
with phenol-chloroform. The aqueous layer was made
0.3M with NaOAc and RNAs precipitated with ethanol.
To control for the DNAse digestion, pure genomic DNAs
(0.1mg) from tumour cells or cell lines were similarly
treated with DNaseI and the products, DNA (T), used
in PCR experiments as controls to monitor for the
ampliﬁcation of possible contaminating DNA. To detect
BHLF1 and LF3 transcripts, expressed from diﬀerent
promoters by reverse transcriptase polymerase chain
reaction (RT-PCR) techniques on the respective RNAs,
ﬁrst strand cDNAs were generated using gene-
speciﬁc primers, that is: for BHLF1, 50-GGTCCCCATG
GCACAGGCCTAG (40261–40280; H-1T) and for LF3,
50-CTGCAGCCGGGTCCGGGGTT (143189–143208;
Ia-IT).
The resulting cDNA was diluted (100ml) in l0mM
Tris–HCl (pH 8.0), 0.1mM EDTA and ampliﬁed using
a variety of primers taken either from the top
(designated T) or bottom (B) strands of the conventional
map of EBV.
For BHLF1, these (given in 50–30 orientations) are
as follows:
GCCCAGCGCGCCCCGTTCA (40303–40321; H-2T);
GGGAGGACCGCGGCCGAGCCA (40325–40345; H3T);
GAGCAAGAATAAGGACGGCTC (41448–41468; H-4T);
GGTTAGTGATGAAACAGGCAAC (41514–41493; H-5B);
CGCTCGGGGGGTGCACACCT (40485–40466; Ia-3B);
GCTCCGCCTACCCCAAATCTC (40728–40708; Ia-4B);
CATTATCCTGGAGGTATCCTAAG (40833–40855; Ia-5T);
GGGGCGGAGCTTAGGATACCTC (40862–40841; Ia-5B);
GAAGGGTGGCGCACCTTAAGG (40952–40932; Ia-6B);
CACGCGGGGTGCCACGTCACC (41164–41144; Ia-7B);
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For LF3, they are as follows:
GGTCCGGGGTTCCGGCCCTG (143198–143217; Ia-2T);
CTCCGGCGGGGATGGGGGTGC (143271–143291; Ia-3T);
CTCCGGCGGGGGGTGGGGATG(143271–143291;C15-3T);
CGCTCGGGGGGTGCACACCT (143403–143384; Ia-3B);
GCTCCGCCTACCCCAAATCTC (143647–143627; Ia-4B);
CATTATCCTGGAGGTATCCTAAG (143752–143774; Ia-5T);
GGGGCGGAGCTTAGGATACCTC (143783–143762; Ia-5B);
GAAGGGTGGCGCACCTTAAGG (143871–143851; Ia-6B);
CACGCGGGGTGCCACGTCACC (144082–144062; Ia-7B);
TTGCCTGCCTCACCATGACAC (144246–144266; Ia-6T);
ACCCTCACCCCATTGCCAACT (144400–144380; Ia-8B);
GCGCCCATTAGAATCTGCTCG (144669–144649; Ia-9B);
GATTCTATTAATAAAACAAGAGAG (144704–144681; Ia-10B);
AACAGGTGTGCAGGTGTGCAT (144791–144771; Ia-11B).
Sequences were chosen by their proximity to potential
‘TATA’ box-like sequences in the DNA and genome
numbers taken from a composite of B95-8 (5) and Raji
(33) sequence that accommodates the EBV genomic
deletion in the former, accession number AJ507799. For
RT-PCR experiments, products were separated by elec-
trophoresis and identities in most cases veriﬁed by
Southern blot hybridization using appropriate radioactive
probes (from the above list; see Figure legends) as
previously described (23).
RNase protection assays
Construction of plasmids H-390, Ia-382, and Ia-330
DNAs. DNA templates for the synthesis of RNA
probes, prepared from DNA fragments H-390 (positions
40266–40657 in BamHI H), Ia-382 (positions 143193–
143575 in BamHI Ia) and Ia-330 (positions 143752–
144082 in BamHI Ia) were introduced into multicloning
sites of the Bluescript SK vector. To facilitate RNA
synthesis, plasmid DNAs were linearized by appropriate
enzymes, depending on the insert orientation, in the
multicloning site between the insert and the T3 or T7
promoters. Riboprobes, oriented from left to right on the
conventional map of the EBV genome were generated for
identifying RNA initiation sites oﬀ diﬀerent promoters.
Construction of plasmid Ia-406 DNA. To explore tran-
scriptional expression from the strand complementary to
the LF3 gene, a cDNA clone, 14A, containing the IR4
repeat sequences from a C15 xenograft cDNA library (34),
cloned into the pBIIKS vector, was cleaved by XbaI and
transcribed by T3 RNA polymerase to generate a ribop-
robe oriented from ‘right to left’ on the EBV genome.
Hybridization of this probe with total RNAs from
BL-derived cell lines, or from C15, produced negative
results in all cases, conﬁrming that there is no transcript
on the opposite (top) strand within the IR4 repeat region
itself, in the EBV genome. To search for transcripts
expressed on the complementary (top) strand upstream of
this repeat, within the promoter (P1) region (15), the
above experiments were repeated with a DNA fragment
Ia-406 (positions 143781–143375 in BamHI Ia) using the
same vector, restriction enzyme and T3 RNA polymerase,
to generate a riboprobe also orientated from ‘right to left’
on the genome, within the DR region containing
EBV oriLyt sequence. This probe was used in RNAse
protection assays to hybridize with total RNAs from
various cell lines.
Radiolabelling of riboprobes by in vitro transcription of
plasmid DNA (adapted from ref. 35). Single-stranded
RNA probes were generated from linearized plasmid
DNAs with DNA-dependent RNA polymerase:
Linearized template DNA (0.6mg) was dissolved in
DEPC-H2O (10ml) in a 1.5ml RNase free Eppendorf
tube, together with 10  transcription buﬀer (2ml)
(Promega), 0.1M DTT (2ml), rNTP mix (A, U,
G¼5mM, C¼0.5mM) (2ml) and RNase inhibitor (1ml;
10u/ml). [a-
32P]-CTP (2ml; 40mCi/ml) and RNA
polymerase (1ml; 20u/ml) were added with mixing, and
the reaction incubated at 378C for 1h. DNase I (1mlo f
1mg/ml) was then added and the reaction further incubated
for 15min at 378C to digest template DNA. Proteins were
removed by extraction with an equal volume of phenol-
chloroform. To purify residual synthesized RNA, the
aqueous layer was transferred into a new tube. 3M
NaOAc (0.1 vol.) and ice-cold ethanol (2 vols.) were added
to precipitate the RNA and, after 30min at  208C, the
tube was centrifuged at 12000g (10min) at 48C and the
ethanol supernatant removed. The opened tube was left at
room temperature (several minutes) to allow residual
ethanol to evaporate, the RNA pellet was dissolved in
TE buﬀer (200ml, pH 7.5), ice-cold ethanol (2 vol.)
was added, and the sample stored at  708C prior to use.
For hybridization, a sample aliquot was withdrawn,
3M NaOAc (0.1 vol.) was added, and the tube left
 208C (30min), then centrifuged. After ethanol removal,
the radiolabelled RNA probe was dissolved in a desired
volume of hybridization buﬀer from a RPAIII kit
(Ambion Biotechnology).
Hybridization and RNase digestion. Total RNAs (100mg
from M-ABA and C15, and 30mg from other cells) were
hybridized with radiolabelled RNA probes (see earlier).
The products were digested with RNase and puriﬁed with
an RPAIII kit (Ambion Biotechnology), according to the
manufacturer’s instructions.
Autoradiography of RNase-protected products. Protected
fragments were suspended in electrophoresis loading
buﬀer, boiled (5min), chilled on ice, centrifuged brieﬂy,
then separated by electrophoresis on a 6% polyacrylamide
gel at 1kV (28mA) for 2–3h. Simultaneously, comparable
amounts of unhybridized and undigested RNA probe
were diluted 500–1000 times in loading buﬀer, and
electrophoresed to allow the full length RNA probe size
to be identiﬁed. After electrophoresis, the gel was ﬁxed
in 10% acetic acid (20min), dried under vacuum and
autoradiographed.
RESULTS
Transcriptional expression of BHLF1 (IR2-containing) and
LF3 (IR4-containing) genes—general findings
Published work (16, reviewed 12, 21) has focused mainly
on expression of the BHLF1 gene—deleted in toto in the
BL-derived cell line Daudi (31) as shown in Figure 1.
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a single-stranded DNA binding protein (25); a similar
property was proposed for the LF3 gene product (24).
In our earlier work (22), transcriptional expression of
BHLF1 was identiﬁed in primary endemic Burkitt’s
lymphoma (BL) biopsies and in most BL-derived cell
lines, but not in several Asian nasopharyngeal carcinoma
(NPC) biopsies, nor in two North African NPC xeno-
grafts, C17 and C18 (32). By comparison, LF3, except for
B95-8 (gene deleted), appeared to be transcriptionally
expressed in both epithelial and B-cell malignancies.
To conﬁrm these data, we looked at transcriptional
expression in a greater variety of materials, using RT-PCR
assays that allowed us to make comparative analyses of
gene expression of BHLF1 and LF3 in EBV-associated
fresh tumour biopsies, as well as in B-cell lines. In the case
of BHLF1, again—with the exception of a late passaged
North African NPC xenograft, C15 (32)—no expression
was observed in epithelial (carcinoma) cells from similar
xenografts, C17 and C18, nor seven new Chinese NPC
biopsies. Interestingly, this transcript was identiﬁed in the
M-ABA B-cell line, generated with virus from an Asian
NPC, but was not identiﬁed in a comprehensive cDNA
library from an early passaged C15 tumour (34), indicative
of alterations in EBV gene expression in diﬀerent cellular
environments, or when subjected to pressures during
tumour passage in vivo. In comparable studies, 11 out of
12 new African BL samples gave bands consistent with
BHLF1 gene expression; identities could be conﬁrmed in
10 cases by hybridization. The data (not given, but
summarized in Tables 1 and 2) also showed expression
levels among these BLs to vary considerably, from very
high to barely detectable, using comparable quantities of
products. All BL-derived cell lines, except for Ramos
(EBV-negative) and Daudi which served as controls, were
positive. Recent sequence data on EBV virus from an
NPC patient (36) or from an A-strain virus (37) show
sequences in this region of the viral genome to be highly
conserved and to resemble strongly those reported earlier
(5,33). Since our protocols also allowed for minor
sequence variations, the data must have reﬂected either
varying viral loads in diﬀerent tumours, or a marked
diﬀerence in levels of cells escaping latency.
LF3 transcriptional expression, by contrast, using the
same tumour populations and cell lines, was observed in
all NPC and BL biopsy materials, as well as in the B-cell
lines—except Ramos and B95-8—at levels that were
generally more homogeneous than seen in the case of
BHLF1.
These data conﬁrm the cell-type bias in gene expres-
sion for BHLF1 suggested earlier (22,23) and the
apparent non-cellular restricted transcription of LF3.
In the M-ABA cell line, transcriptional expression from
a pair of contiguous promoters (P1) was reported as
being dependent on the presence of chemical inducing
agents (15). With the sensitive RT-PCR assays, we
identiﬁed transcripts for BHLF1 and LF3, even in
the absence of induction. Our Northern blot data (22,30)
on B-cell lines showed, however, that chemical induction,
although not absolutely essential, generally increased
transcription levels, in some cases to a very
considerable degree. The RT-PCR data reported earlier
(22) and conﬁrmed here hinted, in addition, at usage of
transcriptional promoters ‘upstream’ (that is, 50) of P1, a
topic followed up in subsequent studies reported here.
50 ends of BHLF1 andLF3 mRNAs, asidentified
by RNase protection assays (RPA)
To explore transcriptional initiation sites for BHLF1 and
LF3 genes, RNase protection experiments were carried
out using B-cells grown in the absence ( ) or presence (þ)
of chemical inducing agents. For BHLF1, the RPA
(Figure 2A), when hybridized with a
32P-radiolabelled
490 base riboprobe, H-390 (positions 40266–40657)
(Figure 2B) from the B95-8 genome, identiﬁed two closely
spaced (20nt apart) RNase-protected bands, arising from
P1 and previously described in M-ABA cells (15), in all
Table 1. RT-PCR results on EBV BHLF1 transcripts in tumour
biopsies and cell lines
a
Promoter-related (P1)( P2)( P3)
primers H-1TþIa-3B H-2TþIa-4B Ia-6TþH-5B
Tumours and Products
cell lines 40261–40485
b 40303–40728 41345–41514
C15 þþ
c þþ
C17    
C18    
NPC1    
NPC2    
NPC3   ND ND
NPC4   ND ND
NPC5   ND ND
NPC6   ND ND
NPC7   ND ND
C15 DNA þþ þþ þþ
CC    
BL-1 þþ    
BL-2 þþ    
BL-3 þþ þ  
BL-4 þ  
BL-5 þ  
BL-6 þþþ ND ND
BL-7   ND ND
BL-8 þ ND ND
BL-9 þ ND ND
BL-10 þ ND ND
BL-11 þþ ND ND
BL-12 þþ ND ND
B95-8 DNA þþ þþ þþ
Daudi( )   þ þ
Daudi(þ)   þ þ
M-ABA( ) þþ þþ þþ
M-ABA(þ) þþ þþ þþ
Raji( ) þþ þþ þþ
Raji(þ) þþ þþ þþ
P3HR-1( ) þþ þþ þþ
P3HR-1(þ) þþ þþ þþ
B95-8( ) þþ þþ þþ
B95-8(þ) þþ þþ þþ
aRT-PCR products conﬁrmed by Southern blot hybridizations, and in
some cases by RNase protection experiments.
bFrom accession number AJ507799.
cþþþ, very strongly positive; þþ, strongly positive; þ, weakly positive,
 , negative, as determined by hybridization under identical conditions
and ND, not done, respectively.
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mapped mRNA initiation sites from this P1 pair to
genome positions 40520 and 40500, respectively, within
the DL region of the viral genome. The levels of protected
RNA in reproducible experiments were of unequal
intensities in diﬀerent lines, as indicated by autoradio-
graph times given on the gels (Figure 2A), the larger
transcript (upper band) being the more abundant of
the two RNAs. In uninduced C15 NPC, the smaller band
was only evident on very long exposures.
Similar RPA experiments were carried out with respect
to LF3 transcripts (Figure 3A), using a radiolabelled 500
base riboprobe, Ia-382 (encompassing genome posi-
tions 143193–143575, partly within DR, Figure 3B).
They identiﬁed one major protected fragment (225nt) in
all samples except that from B95-8 cells. In RNAs from
induced cells, a minor, larger, band (245nt) was also
observed in Daudi and P3HR-1 cells. A negative result with
B95-8 is consistent with this product coming from LF3,
rather than the BHLF1 region of the genome (Figure 1). In
the lower portion of this gel, bands (in B95-9, M-ABA and
Raji cells) are attributable to cross-hybridization with
transcripts expressed from DL whilst bands observed in
Daudi and P3HR-1, with aberrant sizes, are likely to be
cross-reacting artefacts. The data for LF3 transcripts are
consistent with Northern blot hybridization data (22) and
suggest that the ﬁrst (P1 pair) promoter site for LF3,
although sensitive to chemical induction, is also active to a
lesser extent in uninduced B-cells and in the C15 tumour.
Also for LF3, in contrast to BHLF1, the smaller RNA
(lower band) of the P1 pair is found to be the more
abundant in all cells examined.
Identification ofunique multiple ‘upstream’ transcriptional
initiation sites forBHLF1 and LF3genes
In RT-PCR conﬁrmatory experiments, in addition to P1
some minor higher molecular weight band products,
Table 2. RT-PCR results on EBV LF3 transcripts in tumour biopsies and cell lines
a
Promoter-related (P1) (P2) (P2) (P3) (P4) (P4) (P4) (P4)
Primers Ia-2TþIa-3B Ia-2TþIa-4B Ia-2TþIa-5B Ia-2TþIa-6B Ia-6TþIa-8B Ia-6TþIa-9B Ia-6TþIa-10B Ia-6TþIa-11B
Product
Tumours
and cell lines
143198–
143403
b
143198–
143647
143198–
143783
143198–
143881
144246–
144400
144246–
144669
144246–
144704
144246–
144791
C15 þþ
c þþþþND þ 
C17 þþþþ ND   
C18 þþþþ ND   
NPC1 þþþþþND þ 
NPC2 þþþþþND þ 
NPC3 þ ND ND ND ND ND ND ND
NPC4 þ ND ND ND ND ND ND ND
NPC5 þ ND ND ND ND ND ND ND
NPC6 þ ND ND ND ND ND ND ND
NPC7 þ ND ND ND ND ND ND ND
C15 DNA þþ þþ þþ þþ þþ ND þþ þþ
CC      ND   
BL-1 þþþþþND   
BL-2 þ þ þþþþND   
BL-3 þþþþþND   
BL-4 þþþþþND   
BL-5 þþþþþND   
BL-6 þ ND ND ND ND ND ND ND
BL-7 þ ND ND ND ND ND ND ND
BL-8 þ ND ND ND ND ND ND ND
BL-9 þ ND ND ND ND ND ND ND
BL-10 þ ND ND ND ND ND ND ND
BL-11 þ ND ND ND ND ND ND ND
BL-12 þ ND ND ND ND ND ND ND
Daudi DNA þþ þþ þþ þþ þþ ND þþ þþ
B95-8       ND  
M-ABA ( ) þþþþþ(þ)N D  
M-ABA (þ) þ þ      ND  
Raji ( ) þ þ þþþ  ND  
Raji (þ) þ þ þþþ  ND  
Daudi ( ) þþþ þþ þþ þþ þ þ ND  
Daudi (þ) þþþ þþ þþ þþ þ þ ND  
P3HR-1( ) þþþ þþ þþ þþ þ þ ND  
P3HR-1(þ) þþþ þþ þþ þþ þ þ ND  
Daudi DNA þþ þþ þþ þþ þþ þþ ND þþ
aData with Ia-6TþIa-8B based on ethidium bromide stained gels, all other products conﬁrmed by Southern blot hybridisation of RT-PCR products.
bfrom accession number AJ507799.
cþþþ, very strongly positive; þþ, strongly positive; þ, weakly positive;  , negative, as determined by hybridisation data under identical conditions,
and ND (not done), respectively. Some data taken from (22,23).
3396 Nucleic Acids Research, 2007, Vol. 35, No. 10lying in the ‘core’ lytic origin sequences, were identiﬁed,
both in ethidium bromide stained gels and blots
hybridized with
32P-radiolabelled probes, suggesting
that RNAs were also being expressed from promoters
50 to P1. To explore ‘upstream’ transcriptional expres-
sion (that is, 50 to P1 in the leftward transcripts) at what
might prove low levels, since it has not been previously
reported, we used RT-PCR initially as a diagnostic
protocol because of its sensitivity. Data covering these
regions of BHLF1 and LF3 are shown in Figure 4,
panels A and B, respectively.
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Figure 2. P1 promoter usage for BHLF1 transcription, mapped by
RPA. RNase protection experiments carried out on total RNAs from
EBV-positive B-cell lines and the C15 NPC xenograft, as indicated, to
re-examine P1 promoter usage for BHLF1 in a semi-quantitative
manner, and in relation to LF3 (Figure 3). (A) Protected products from
chemically uninduced ( ) or induced (þ) cells, as indicated, run on gels
and identiﬁed using the
32P-radiolabelled cloned riboprobe, H-390.
Bands at 254 and 234 bases (arrows) were obtained from all except
substrates from Daudi, P3HR-1 and the yeast negative control.
Intensities of the larger protected fragment are ca.4   that of the
smaller product suggesting that, of the P1 pair, the site further from the
gene itself is the stronger. Gels shown were developed at times indicated
to illustrate comparable cellular product levels, in all except C15, where
bands were consistently weak. (Not shown are smaller cross-hybridizing
protected bands relating to LF3, observed with all but B95-8
substrates). M¼molecular weight size markers. (B) Diagram (with
nucleotide numbers) showing features of the BHLF1 gene, including its
mRNA 50-ends as initiated from P1 (doublet, vertical arrows), 30-ends
of deletions found in P3HR-1 and Daudi cells (light brackets) and site
locations of the DL termini (heavy brackets). The location and
nucleotide numbers of the RNA probe, H-390, and the protected 234
and 254 base products (in 2A) lying within DL (134 and 154 bases,
solid bars) or within BamHI unique sequence (100 bases, hatched bars),
are indicated. Location of the promoter signal probably controlling
transcriptional expression of BHLF1 (50GATAAA, position 40529)
is indicated by dashed lines.
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Figure 3. P1 promoter usage for LF3 transcription, mapped by RPA.
(A) RNase protection data, using cell lines, as indicated, here exploring
further the role of chemical induction on transcription by including
pairs of corresponding RNAs from uninduced ( ) and induced (þ)
cells, as indicated. With the
32P-radiolabelled Ia-382 riboprobe, a major
protected LF3 band of 225 bases, highly sensitive to chemical
induction, was observed (in all but B95-8 cells), and very minor
bands (at 245 bases) are seen in induced Daudi and P3HR-1 cells.
Notably, for LF3, as opposed to BHLF1 (Figure 2A), the smaller
product predominates, suggesting the major use of the P1 pair nearest
the gene. Bands at 154 and 134 bases, also present in B95-8, reﬂect
cross-hybridization of the probe with the DL BHLF1 transcript.
(Random-sized bands in Daudi and P3HR-1 cells are artefacts of the
protocol). (B) Diagram (with nucleotide numbers) showing features,
as noted in the legend to Figure 2, using sizes and numbers that
correspond to the LF3 gene. The location and nucleotide numbers of
the RNA probe, Ia-382, and the protected products of 225 and 245
bases (in 3A) lying within DR (134 and 154 bases, solid bars) or within
BamHI Ia IR4 repeat (91 bases, hatched bars), are indicated. Location
of the promoter signal possibly controlling the transcriptional expres-
sion of LF3 (50GATAAA, position 143447) is indicated by dashed lines.
The deletion in B95-8 (not shown) covers this entire region.
Nucleic Acids Research, 2007, Vol. 35,No. 10 3397For BHLF1, among the NPCs examined (panel A),
bands coming from a promoter we designate P2 were—as
with P1—only identiﬁed in C15 xenografts. Using
tumours propagated in the absence ( ) or presence (þ)
of chemical inducing agents, the data showed no evidence
that this RNA product was subject to chemical
induction. Similar ﬁndings were obtained in all the B-cell
lines examined (B95-8, M-ABA, Raji and P3HR-1) where
this gene is present. It was not observed in Daudi cells,
but one of the primers used, H2T, lies within the
deletion in these cells (31, see Figure 1). Whilst active
in established B-cell lines, P2 usage was only observed in
1/5 of the tumour cells—BL3 being the single exception.
We have at present no explanation for this ﬁnding,
although heterogeneity among primary BLs is not
uncommon (3).
Similar experiments on P2 usage for LF3, showed little
diﬀerence among the samples populations, whether from
NPC or BL primary tumours, or established B-cell lines
(Figure 4, panel B). In established lines using both
uninduced ( ) and induced (þ) cells, no diﬀerences in
usage were apparent, suggesting promoter insensitivity
to the action of these agents. The exception to this is
M-ABA, where the promoter appears to be negatively
regulated. Throughout, RNAs from B95-8 were negative,
conﬁrming the nature of the transcript as being derived
from LF3.
Confirmation of the second (P2)promoter by RPA
RNase protection assays were carried out to conﬁrm the
use of a P2 promoter-related sequence for expression
(in part) of BHLF1 and for LF3, to determine the
respective transcript 50-end initiation sites—using a
32P-radiolabelled RNA probe, plasmid Ia-330 (position
143752–144082), constructed for this purpose from Raji
DNA (33)-and conﬁrm its apparent insensitivity to
inducing agents. Hybridization of total RNAs following
RNase digestion using this 440 base riboprobe from the
DS region revealed a single fragment of 45 bases in all
of the cell lines employed, as shown (Figure 5A),
mapping the transcript initiation site for BHLF1 to DL,
at position 40879; for LF3, this site in DR maps to
position 143797 (Figure 5B). The data show transcripts
from P2 in diﬀerent cells to be expressed from
non-inducible promoters, suggesting that they may be
regulated in a manner distinguishable from transcripts oﬀ
P1 promoters which are generally sensitive to chemical
induction.
Mapping LF3promoters P3and P4by RT-PCR
To ask whether there are transcripts being expressed
oﬀ promoters beyond P2, RT-PCR experiments were
further carried out using several diﬀerent sets of primers
and
32P-labelled probes, as found in ‘Materials
Figure 4. RT-PCR detection of upstream promoters, P2, for expression of BHLF1 and LF3. An RT-PCR technique was adapted to identify
potential transcriptional expression of BHLF1 and LF3 from regions upstream of P1. Combinations of H-2T and Ia-4B (for BHLF1), and Ia-2T
and Ia-4B (for LF3) were used for the PCR ampliﬁcations; products were hybridized with
32P-radiolabelled H-3T (for BHLF1), and a combination
of Ia-3T and C15-3T (for LF3) to accommodate minor sequence alterations observed with C15 (our data). Panel A. Promoter ‘upstream’ usage for
BHLF1, identiﬁed as 425bp products from uninduced ( ) or induced (þ) cells, as indicated. There is no evidence that chemical induction alters
transcription from this site, designated P2. Except for the C15 xenograft and BL-3, P2 was not apparently active in other tumour samples (Table 1)
as opposed to cell lines. Panel B. Similar protocols used for studying ‘upstream’ promoter usage for LF3. A product of 449bp was obtained from all
substrates [except those from B95-8, induced (þ) M-ABA cells or EBV-negative controls]. Transcripts in these panels correspond to usage of P2,
a promoter-related site that is not responsive to, and may even be down-regulated (see M-ABA data) by, chemical agents that induce transcriptional
expression from P1.
3398 Nucleic Acids Research, 2007, Vol. 35, No. 10and Methods’, for examining LF3 expression. As shown
(Figure 6, panels a and b), when a combination of primers,
Ia-2T and Ia-6B, was used, the same expression proﬁle
was observed as seen in Figure 4 (panel B, bottom tracts,
using primers Ia-2T and Ia-4B). Since primer Ia-6B is
located ‘upstream’ of the 50-end of the RNA transcribed
from the P2 promoter, these results demonstrate that
transcripts are still being expressed from a third promoter,
P3, in these cell lines. When the combination of Ia-6T
and Ia-8B was used (panel c) Raji cells gave negative
results, suggesting the existence of a P3 promoter
between nucleotide positions 143 851 (Ia-6B) and 144
400 (Ia-8B). Positive bands with Daudi, P3HR-1 and
uninduced M-ABA cells suggested that there should be a
fourth promoter, P4, for LF3, used by these cells, but
not by Raji. When the combination of primers Ia-6T and
Ia-9B was used, and product probed with
32P-radiola-
belled Ia-8B, positive bands were obtained in comparable
amounts in Daudi and P3HR-1 lines (uninduced or
induced) but only at low levels in uninduced and not at
all in induced M-ABA cells (Figure 6, panels d and e). As
there is a TATA box at position 144 720, this signal
probably directs use of the fourth promoter for the
leftwardly expressed LF3 RNAs, from unique sequence in
the genome. Similar experiments carried out with a
combination of Ia-6T and Ia-11B (panel f), hybridized
with radiolabelled Ia-8B, were negative (panel g), setting
an upper limit for transcriptional expression of LF3
at genome position 144 704.
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Figure 5. RPA conﬁrming ‘upstream’ P2 promoter usage for BHLF1
and LF3. (A) Total RNAs from chemically uninduced ( ) or induced
(þ) cell lines (as noted), hybridized with a 440 base riboprobe
transcribed from the DNA clone Ia-330. Bands at 45 bases were
protected from RNase degradation in transcripts from all samples,
except the yeast tRNA control. The data identify usage of the
‘upstream’ promoter, P2, in all EBV-positive cells examined, and are
consistent with P2, unlike P1, being non-responsive to chemical
inducing agents. (B) Schematic diagram showing the gene structure of
BHLF1 and LF3, locations and nucleotide numbers of the riboprobe
Ia-330, and the RNase protected 45 base product within DS.
For BHLF1 and LF3, P2 transcription is initiated at positions 40879
and 143797, respectively. The transcriptional controlling signals for P2
is probably from ‘CATTAAA’ boxes at positions 40970 (for BHLF1)
or 143888 (for LF3).
Figure 6. Mapping of the LF3 promoters P3 and P4 by RT-PCR.
cDNAs were synthesized by reverse transcription of total RNAs from
cell lines, as indicated, using a gene-speciﬁc primer Ia-1T. Primers used
for PCR ampliﬁcations to detect RNA species ‘upstream’ of the P2
promoter are indicated (below) and their locations on the EBV genome
map given in ‘Materials and Methods’. Panel a shows ethidium
bromide stained gel results using primers Ia-2T and Ia-6B in PCR
ampliﬁcations to detect a possible third promoter, P3, and panel b the
same gel hybridized with
32P-labelled Ia-3T. Panel c conﬁrms the data
in a using a diﬀerent set of primers, a combination of Ia-6T and Ia-8B.
Notably, this P3 promoter was not identiﬁed in the case of BHLF1 (see
‘Results’ section). To detect a possible fourth promoter, P4, for the
LF3 transcript, the same cDNA samples were used in further
experiments given in panels d–g. In panel d, primers Ia-6T and Ia-9B
were used and the products probed with
32P-labelled Ia-8B (panel e).
In panel f, primers Ia-6T and Ia-11B were used, with probe
32P-labelled
Ia-8B (panel g). Notably, whereas products were observed in panels
d and e, none were observed in f and g. M-tracks contain size markers,
P-tracks, primers only, and (T)-tracks, DNase I-treated DNA from the
cells.
Nucleic Acids Research, 2007, Vol. 35,No. 10 3399When primers and probes were adapted to assess
BHLF1 expression from possible P3 and P4 promoters,
all cell-line samples used, and the C15 xenograft (but not
other tumours) gave positive results, even when primers
came from outside DL in unique BamHI H sequence.
Thus we could identify no speciﬁc P4 promoter usage
for transcription of this gene. But a P3 promoter
not comparable to that of LF3 P3 (described earlier)
was identiﬁed. We designated this promoter P30.
Although we did not deﬁnitely map it, P30 lies beyond
positive 41 514 in the unique region. In experiments
using primers Ia-6T and H-5B, with a radiolabelled H-4T
probe, positive results were obtained with Daudi,
M-ABA, Raji, P3HR-1 and B95-8 cells, and the C15
tumour. This promoter proved insensitive to inducing
agents, and for BHLF1 gene expression, comparable
results were obtained with M-ABA cells, whether induced
or not (data not shown).
DR
start
143284
DR
144328
Region 1 of OriLyt
143251
143440 143508
Z Z/Ap-1
143572 143835
Region 2 of OriLyt
143970 144057
Z
A, T-rich
Palindrome Z Z
C-rich
inverted repeat
R R Z Z R
SP1
Sp3
Z
B
p
(A)
5′
mRNA
end
~
IR4
140693
3′
Region3 of OriLyt
Primers RT-PCR
results
Promoter
usage
Ia-2T + Ia-3B
H-1T + Ia-3B
Confirmation
by RPA
mRNA
initiation sites
Ia-2T + Ia-4B
H-2T + Ia-4B
Ia-2T + Ia-6B
Ia-6T + H-5B
Ia-6T + Ia-8B
+
+
+
+
+
+
LF3-P1
BHLF1-P1
LF3-P2
BHLF1-P2
LF3-P3
BHLF1-P3′
LF3-P4
Ia-382
H-391
Ia-330
Ia-330
143418 & 143438
40500 & 40520
+
143797
40879
ND
ND
143871 - 144246
> 41514
ND 144704 -144771 
(B)
Ia-3B
Ia
1T
Ia
2T
Ia-4B
Ia
6T
Ia-8B
DR DR P1 P2 P4 P3
* Ia-6B
3′ 5′
Ia-3B
H
1T
H
2T
Ia-4B
Ia
6T
H-5B
DL DL P1 P2 P3
* Ia-6B
3′ 5′
start end
start end
end
Figure 7. Summary of transcriptional responsive elements (TREs) and promoters identiﬁed for BHLF1 and LF3, within oriLyt, as given here for
LF3 and elsewhere for BHLF1 (21). (A) The IR4 repeat region and the 30-mRNA end (single arrow) are indicated. The duplicated sequence (DS)
regions of EBV DNA contain potential structural elements that divide it into three distinct regions, as noted (open brackets). Region 1 contains the
DR start (in LF3at position 143 284; double-headed arrow), as well as the LF3 mRNA start site from the inducible promoter pair, P1 (not shown), a
number of zta (Z or EB1)-responsive elements (in red) and an Ap-1 binding sequence (yellow). The core OriLyt sequence in region 1 is indicated
(closed brackets) and contains ‘TATA’ and ‘CAAT’ boxes (triangles) and TREs, as shown. The P2 non-inducible promoter maps to position 143 797,
between regions 1 and 2. Region 2 contains a DNA sequence that permits formation of three short A,T-rich hairpin loops in BHLF1 (between
positions 40974 and 41044) and in LF3 (between 143893 and 143964), and a putative ‘hinge’ (H) G,C-rich region with triple and single-stranded
components, in BHLF1 (between 41077 and 41140) and in LF3 (predicted, between 143995 and 144023), as well as SP1/SP3 and ZBp TRE elements
(21), as noted. Region 3, further ‘upstream’, contains the 50-end of DR (in LF3at position 144328; double-headed arrow) as well as both Z (red) and
R( rta or EB2, blue) responsive elements, interspersed. These may compete with each other, or alternatively, act cooperatively in transcription events.
Immediately outside the DR region is a further Z responsive element. Sp1, Sp3 and ZBP are cellular transcription factors (21). (B) Summary of
promoter mapping data. To determine the transcriptional expression from diﬀerent promoters, each transcript was ﬁrst detected by RT-PCR (shown
in part in Figures 4 and 6), then ﬁne-mapped and conﬁrmed by RNase protection assays (Figures 2, 3 and 5). RT-PCR data are summarized in
Tables 1 and 2. Another promoter, designated P30, for BHLF1 and P3 for LF3 transcripts, was identiﬁed and partly, but not precisely, mapped in
these studies. For BHLF1, it lay outside DL, whereas for LF3 it was within DR. A fourth promoter, P4, was found for the LF3 transcript and
localized by RT-PCR, outside DR, as shown. It may functionally correspond to P30 for BHLF1, but this is not conﬁrmed. The laboratory data
are compiled here in tabular and linear forms and the precise, or approximate ( ), locations of the various promoter sites within or outside DS,
are identiﬁed for LF3 (P1–P4) and for BHLF1 (P1–P30). PCR primers used in each case (see ‘Materials and Methods’) are given for each gene, and
their locations noted.
3400 Nucleic Acids Research, 2007, Vol. 35, No. 10These data are summarized in Figure 7A, together with
locations of some known transcriptional transregulation
functions (viral and cellular). Of note is a ‘zeta’ transcrip-
tional activation motif just 50 to the DR regions.
Identification ofoverlapping, non-coding ‘rightward’
(antisense) transcripts
To search for complementary strand RNAs, suggested
by examining the primary structure on the strand
complementary to BHLF1 and LF3 genes, and potential
promoters, we initially generated a cDNA riboprobe,
14A, transcribed from ‘right to left’ on the EBV genome,
containing the IR4 repeat sequences from the C15
tumour (34). When this
32P-radiolabelled probe was
hybridized with total RNAs from a variety of cell lines
or the C15 tumour itself, and products subjected to RNase
digestion, only negative results were obtained (data not
shown), suggesting no transcription on the opposite
strand, within the main body of the coding region of
LF3 (38).
In a second set of experiments, similar RNase
protection assays were carried out with another
32P-radiolabelled complementary strand riboprobe,
Ia-406 (nucleotides 143781–143375) that incorporated
the ﬁrst promoter (P1) region of the LF3 gene and part
of the ‘core’ oriLyt sequences. When Ia-406 was hybri-
dized with total RNAs from B95-8 [uninduced ( )o r
induced (þ)], Raji ( ), Daudi ( ), BL74 (þ) and P3HR-1
( ) cells, after RNase digestion a series of 9–10 related
protected bands were observed (Figure 8A). Although the
bands varied in intensity among transcripts derived from
diﬀerent cells, the product patterns were similar or
identical. Multiple bands were observed in all samples
(except control, yeast tRNAs).
This family of RNA molecules—transcribed with the
opposite polarity to the BHLF1/LF3 transcripts—was
initiated within the so-called ‘upstream region’ of EBV
oriLyt (8) and extended into the ‘downstream’ region
(Figure 8B). Transcripts were identiﬁed in both B95-8 and
Daudi cells indicating that both DL and DR support the
expression of ‘antisense’ transcription. The promoter
region, as mapped for the largest of the transcripts,
notably overlaps that of the inducible P1 regions for
BHLF1 and LF3.
DISCUSSION
EBV lytic replication has been a subject of intense,
but sporadic, attention in a number of laboratories for
at least 20 years (8, reviewed 6,12,21,39). Two nearly
identical viral repetitive sequences (DS), with oriLyt
activity, fulﬁl this role for EBV. These lie about
40000bp from each end of the linear viral genome and
are designated DL and DR—that is, left and right
duplications of DNA. In addition to containing the
‘core’ sites, or origins, of lytic replication, the duplications
also contain strong promoters for the major mRNAs
found in many EBV-related cell lines and tumours.
These control expression of two viral ‘early’ genes,
BHLF1 (associated with DL) and LF3 (with DR), each
of which speciﬁes a protein. These genes are transcribed
from ‘leftward’ transcripts on the conventional map of
EBV DNA (Figure 1). Most viral strains contain both
genes and their associated DS regions, but some have
lost one or other of them—not both—yet remain viable.
The two repetitive elements themselves do not reside
within identical genetic environments and data reported
elsewhere (22,23), and conﬁrmed in the present study
(summarized, Tables 1 and 2), show that they may also
be diﬀerently regulated. For example, whereas LF3
expression can be identiﬁed in tumours of both lymphoid
(Burkitt’s lymphoma, BL) and epithelial cell (nasopha-
ryngeal carcinoma, NPC) origins, in general BHLF1
expression seems largely conﬁned to the former.
Our interest in the two viral components, DL and DR,
their usage and in turn the genes they control, stems
initially from the assumption that studying them in
concert might identify sequences that could be used to
regulate EBV lytic replication in a cell-type speciﬁc
manner. And further—since in the case of ‘endemic BL’
(3,40,41) genes associated with EBV lytic replication
appear to mark tumours most likely to respond to
simple chemotherapy—in the longer term such studies
might prove of relevance to tumour control. The data we
present here concern transcriptional control of BHLF1
and LF3, and suggest roles these genes might have in
controlling viral lytic replication.
From earlier studies, EBV lytic replication has been
shown to be dependent upon transcription (8), and to be
tightly controlled by, or dependent on, expression of
two viral genes originally designated EB1 and EB2 (13),
and later also BZLF1 (Zebra, zta) and BRLF1 (Rta),
respectively (18). Lytic replication may be enhanced by
transcription inducing agents such as the tumour promo-
ter, phorbol 12-myristate 13-acetate (TPA), histone
deacetylase inhibitors such as n-butyrate or surface
immunoglobulin cross-linking agents (discussed 6,9,14).
Our studies here reveal the apparent complexities of
promoters used for transcription of these two genes, with
at least four distinct promoters used for expression of
LF3, three of which are also probably involved in
expression of BHLF1. Most of these promoter-related
sequences lie within DL and DR, but only one of them
(designated here, the P1 pair; ref. 15), but not the others,
appear responsive to chemical inducing agents. Moreover,
at least one promoter identiﬁed for each gene lies in
unique DNA regions, outside DS, allowing possibly for
diﬀerential responsiveness to transcriptional activators
or repressors, and interactions with host-cell functions.
Since the promoter elements identiﬁed mostly (or all)
contain one or more typical ‘TATA’ and ‘CCAAT’ boxes,
and their transcripts contain ‘AATAAA’ polyadenylation
signals (22), we assume, but have not proved, that they are
transcribed by RNAse Pol II. Our data on these
transcripts are summarized in Figure 7, and evidence
leading to this summary ﬁgure is presented in Figures 2–6
and Tables 1 and 2. Whether transcripts expressed from
each of these promoters are translated is yet to be
determined. This need not be the case. Interestingly,
the role of the proteins associated with BHLF1 (25)
and LF3 (24) also remains unknown, but both are highly
basic and known to associate with DNA. The structure of
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Figure 8. Identiﬁcation of complementary (rightward) strand transcripts by RNase protection (RPA) assays. (A)A
32P-radiolabelled 520 base
riboprobe (Ia-406, see track, Riboprobe) from the DR region of the viral genome was used in RPA assays to explore ‘rightward’ transcription on the
strand complementary to LF3, that is, in a ‘rightward’ direction on the EBV genome (Figure 1). In cells, as noted, a series of small, overlapping
products were observed as seen here. Due to deletions in their respective genomes, bands in B95-8 cells must arise from the DL region and in Daudi
cells from DR. Raji, BL74 or P3HR-1 bands may represent mixtures of products from both DL and DR. Notably, the patterns are identical,
although band intensities vary. For BL74, bands were only observed in induced cells, as shown, which was not the case with other lines. Data given
here use a low-speciﬁc activity probe, in great excess. Larger bands appear more prominent in uninduced cells, with induction appearing to favour in
general the smaller bands. M¼molecular weight markers; size calculations of protected bands are given (arrows). (B) An illustrative diagram
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events inherent in its small tandem 102bp repetitive
sequences, may be highly variable within EBV from
diﬀerent individuals (38). We proposed that such data are
consistent with a molecular mechanism that permits their
escape from immune surveillance.
In the present article, our transcription data show that
chemical induction, known to increase lytic replication,
generally increases expression from P1 at the expense of
the alternative, non-inducible, promoters identiﬁed. Our
data raise important questions concerning the role(s) of
the latter promoters. We address this topic from several
points of view. We question whether they, one or all,
might act as replication primers or whether one or more
of their products might play roles in the maintenance of
latency. We argue that such transcripts may all be part
of a complex lytic replication pathway used by EBV.
With regard to these questions, by virtue of their
orientation, the viral ‘leftwardly’ transcribed RNAs must,
in crossing the lytic origin ‘core’ sequences, pass sequen-
tially ﬁrst through the postulated G,C-rich ‘hinge’
structure (16) before encountering less-stable short
A,T-rich palindromic loops (Figure 7A). Without ‘help’,
it seems energetically unlikely that transcripts from P3/P4
for LF3, or P30 from BHLF1, would thus function as
the required transcriptional adjuncts (8) to EBV lytic
replication. Were speciﬁed translation products (from P1
and P2) to act as replication-speciﬁc DNA binding
proteins, on the other hand, this apparently energetic
unfavourable event might receive ‘support’, i.e. allow for
strand separation. Or, if their transcripts speciﬁcally
bound to DNA sites that contain the G,C-rich inverted
structure, or a hinge variant of it, then, again, they might
contribute directly to lytic replication. In preliminary
work, however, we did not detect these transcripts in
association with DNA, arguing against the latter sugges-
tion. Notably, the promoters that we designate P30 for
BHLF1 (Table 1) and P4 for LF3 (Table 2) are located
50 to the ‘core’ lytic origin of replication, outside DS
(Figure 6). Transcribed products from such promoters
must cross this entire origin sequence, potentially desta-
bilizing it and assisting in the generation of a hinge
(H)-sequence that would release a single-stranded loop
in the genome for lytic replication, as projected (16).
It seems energetically unlikely, however, that such a
structure would persist in the absence of a lytic
origin-binding protein.
In proposing that the very basic (arginine/histidine-rich)
LF3 and BHLF1 translation products might themselves
fulﬁl a role in lytic EBV replication—by speciﬁcally
binding components of the origin sequences in the viral
DNA, and stabilizing them—we are confounded by the
problem that a dedicated EBV oriLyt-binding protein was
not identiﬁed in early in vitro studies aimed at deﬁning
viral proteins associated with lytic replication (26,27).
From these published data, the conclusion allowed was
either that a dedicated EBV origin-binding function is not
required for lytic replication or, alternatively, a cellular
function may fulﬁl this role. There is another explanation,
however. That is, the Vero cell line in which these in vitro
replication experiments were carried out might have
supplied this function, not from its host genes but from
the virus it harbours. Vero is derived from a New World
primate and is now known to harbour its own endogenous
herpesvirus, whose DNA sequence bears many homol-
ogies with that of EBV (42). These include genes
structurally related to the EBV IR2- and IR4-containing
genes, BHLF1 and LF3. Thus, proteins in the VERO cells
could have provided in-trans the origin-binding functions
for EBV lytic replication, in the earlier studies. If so,
then arguably, the leftward transcripts might be essential
components of viral lytic replication, helping with
‘opening up’ the energetically tight structures in the
OriLyts to allow replication to proceed.
Evenso, it is obvious that a more energetically favour-
able sequence of events would result if, in transcrip-
tion events, the small, less stable, A,T-rich hairpin
loop structures in the oriLyts were encountered
initially, followed then by the putative ‘hinge regions’
(15, see Figure 7A). We thus examined the possibility of
transcription events occurring on the complementary
DNA strands of DS. Using RNase protection assays
and total cellular RNAs from a variety of cell lines, small
protected bands, of varying lengths, were indeed identiﬁed
(Figure 8A and B). These ‘rightwardly transcribed’
overlapping RNAs transverse oriLyt sequences with a
polarity that should be energetically preferred, as argued
earlier, permitting them to encounter sequentially ﬁrst
the A,T-rich palindromes, then the ‘hinge’ sequences.
As such, they could provide potential primers for DNA
polymerase and serve direct roles in lytic replication.
Their most 50-end initiation site is adjacent to, and
possibly overlaps, the P1 promoters identiﬁed earlier for
the ‘leftwardly’ expressed transcripts (15). (They terminate
beyond DS at a site we have yet precisely to identify.)
In the tumour cell line, BL74, chemical induction was
apparently necessary for their transcription, but in other
cells a role for inducing agents was less clear (Figure 8A).
We found such ‘rightward’ transcripts in both B95-8,
Daudi/P3HR-1 and other cells, suggesting transcription
from both DL and DR. Our data, which were reprodu-
cible, do not show whether the variable 50-ends of these
small ‘rightwardly expressed’ RNAs represent primary
transcription events or, alternatively, cleavage products of
an RNA/DNA hybrid using host enzymes (43).
In preliminary studies, again we did not identify RNA/
DNA hybrids. Notably the sequence of the ‘rightward’
strand—complementary to that containing the promoters
mapped for BHLF1 and LF3 and the respective genes
themselves—contain ‘TATA’-box initiation sites, in
showing location and nucleotide numbers of the riboprobe (Ia-406) and the protected products from the rightward ‘complementary strand’
transcripts, relative to the BamHI Ia fragment in the EBV genome (33) and DR (between heavy brackets). The locations of the leftward promoter-
related sequences, P1–P4 (single-headed arrows) and LF3 mRNA start sites (bent arrows, below horizontal line), both below the horizontal line, are
shown. The 50-end initiation sites of ‘rightward’ transcripts over this same region are indicated (bent arrows) above the horizon line. If expressed
simultaneously in cells, the rightward strand transcripts would overlap leftward transcripts, possibly to form double-stranded RNAs which, as such,
might be targeted for degradation by cellular enzymes. ( )¼mapped only approximately.
Nucleic Acids Research, 2007, Vol. 35,No. 10 3403suﬃcient numbers to account for the nine major products
observed (Figure 8)—suggesting these may be primary
transcription products. In the absence of data to the
contrary, we propose that the polarity and properties of
the ‘rightward’ transcripts suggest they also may represent
events directly associated with the control of EBV lytic
replication. As ‘antisense’ RNAs, they may block
transcription on the other strand from some of the
promoters, or vice versa.
Basically, we show here that BHLF1 and LF3 genes
reside in highly complex regions of the EBV genome,
and that this complexity is reﬂected in respective
transcriptional events, most likely associated with
viral lytic replication and/or blocking this event. One
possible pair of promoters, but probably not the others,
respond to chemical inducing agents. Like their
positions in the genome, these viral genes possess both
numerous similarities and diﬀerences that may be
exploited in diﬀerent cell types. The identiﬁcation of
three viral products surrounding the oriLyt regions—that
is, RNAs that are transcribed from both strands of the
viral DNA, and possible DNA-binding proteins (24,25)
speciﬁed by transcripts from one of the two strands—is
reminiscent of the model deduced for ColE1 plasmid
replication in the elegant studies of Tomizawa (reviewed,
44) and colleagues. Their ﬁndings may thus provide a
useful model for further studies relating to EBV lytic
replication.
We entertained the possibility that these small,
‘complementary’ RNAs (Figure 8A) act as ‘classical’
micro (mi) RNAs. However, although miRNAs have been
identiﬁed elsewhere in the EBV genome (45–47), they have
not been found within DS. We cannot at this stage exclude
the possibility that the transcripts may function as small
interfering (si) RNAs, although these species appear
to arise from double-stranded precursors, which is not
obviously the case here.
EBV BHLF1 and LF3 genes are so-called ‘early
antigens’, and cells in which the virus can be induced to
synthesize early antigens are targeted for cell death.
Moreover, lytic cycle repression is important for tumour
maintenance. One of the prime reasons in studying
EBV lytic replication must lie with the potential for
exploiting knowledge derived for ‘translational research’
programmes aimed at tumour control (3,48). Field
studies on BL patients suggest that stimulating the
B-cells to undergo lytic replication increases their respon-
siveness to ‘classical’ chemotherapy protocols (40,41).
Immunohistochemistry studies show that the LF3-
speciﬁed early antigen co-localizes, in the cell nucleus
and cytoplasm, with both the major viral capsid proteins,
VCAs (our unpublished data), and the viral transcription
transactivator (BZLF1 or EB1) zta protein (38). What the
multiple promoters and antisense transcripts for BHLF1
and LF3 oﬀer us thus is an opportunity, for example,
of using miRNA technologies to study the ablation of
individual promoters in the viral genome, and analysing
subsequent responses by immunocytochemistry or corre-
sponding changes in cellular phenotypes and genotypes
in in vitro studies. Moreover, whereas the ‘leftward’ gene
RNAs have all the hallmarks of RNA polymerase Pol II
transcripts in human cells, the small complementary
‘rightwardly expressed’ RNAs, on the other hand, more
resemble TATA
þ Pol III transcripts (49): there are
numerous ‘TATA’ boxes in the sequence, but no data to
support these RNAs as exons of larger messenger species,
and no obvious polyadenylation (AATAAA) signal in
adjacent downstream viral sequences. The likelihood is
that these ‘rightward’ transcripts may directly interfere
with transcriptional expression of BHLF1 and LF3.
In practical terms, if it should prove that Pol II and
Pol III polymerases invoke ‘leftward’ and ‘rightward’
transcripts, respectively, they may provide alternative
easily deﬁned approaches for further studies on the
control and regulation of lytic replication of this medically
important virus. A third topic to be taken into account is
that of epigenetic events associated with transcription of
BHLF1 and LF3. Our preliminary studies, both in cell
lines and tumours (not shown) identify a considerable
degree of methylation over corresponding regions of the
genome with, for example, many CCGG sequences
lacking sensitivity to cleavage with the methylation-
sensitive HpaII restriction enzyme. Thus epigenetic
events will undoubtedly prove important in unravelling
events relevant to the transcriptional control of
these genes, as well as the ‘rightwardly expressed’
transcripts. Dissecting this important topic will be
complicated by the very large numbers of supposedly
‘rare’ CpG sequences found in these regions (30), on both
strands of the DNA.
We also note the striking question of two apparently
genetic and functionally related sequences in EBV,
since viruses on the whole, by virtue of their size and
dependency on their hosts, have little scope for redundant
information. Gene duplication has been argued to be
a main source of evolutionary innovation in that where
one copy of the gene becomes repositioned—as here—the
creation of a new function may occur (50). For EBV, the
existing data argue against functional redundancy but
rather suggest that duplication may have occurred in the
past to create an extended host range for this virus. For
EBV—and possibly HHV-8 (20)—gene duplication in the
past may represent an expansionist event, a quest for
survival. Notably among DNA viruses, EBV has a
remarkably wide host range (1). In our study, we have
examined transcription in only two (B-lymphocytes and
epithelium) of these cell types, encountering cell speciﬁcity
with regard to expression of the two genes studied,
BHLF1 and LF3. Such speciﬁcities may also exist in
other cell types (T-cells, ﬁbroblasts) associated with this
virus.
Since EBV infection can be associated with
serious pathological consequences for some individuals,
understanding how to control its proliferation is more
than an academic exercise and warrants continued
study. Further examining the rationale and control
of the numerous promoters identiﬁed in our work
will, we trust, oﬀer possibilities for new, future
molecular studies relating to the regulation of EBV
lytic replication, a topic that has proved problemative to
date.
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